Exposure to high doses of gamma irradiation (i.e., 5000 to 10,000
thelial ovarian cancer cells.
The physiologic and cellular changes associated with high INTRODUCTION doses of irradiation have been well documented [for review, see 9]. However, it has only recently been shown that after Cell surface antigens are important for both recognition irradiation an increased synthesis of specific proteins, includand destruction of tumor cells by the host immune system. ing MHC Class I antigens, has been observed. Hauser et For a specific immune response to ensue, T cells must recog-al. [10] reported an increased expression of MHC Class I nize a target peptide in the context of a major histocompatimolecules after fractionated doses of irradiation on a murine bility complex (MHC) 3 molecule. However, additional comelanoma cell line in vitro and Hareyama et al.
[11] demonstrated an increased expression of MHC Class I and carci-1 This work was supported in part by grants from Memorial Health Ser-noembryonic antigen after lethal irradiation of a human gas- High-dose gamma irradiation. Tumor cell lines were autologous human tumor vaccines require methods such as irradiated with 5000 and 10,000 cGy in 15-ml conical tubes irradiation, to inhibit cell replication, so as to prevent possi-in CM at room temperature with gamma rays (Cesium 137) ble tumor formation at the immunization site. Moreover, at a dose rate of 200 cGy/min. Immediately after irradiation, such methods should not compromise the immunogenicity cells were seeded into T 75 tissue culture flasks (Corning, of the tumor vaccine; rather, they should maintain or when Corning, NY) in CM and cultured at 37ЊC in a 5% CO 2 possible enhance its intrinsic immunogenic potential. We atmosphere. Spent media were changed every other day. were incubated for 30 min followed by two washes with assay buffer. Phycoerythrin-conjugated goat anti-mouse IgG Tumor cell lines. Four human epithelial ovarian carci-F(ab) 2 (H&L) (Leinco Technologies, St. Louis, MO) diluted noma cell lines (UCI-101, UCI-107, SKOV-3, and T-222) 1:100 in assay buffer was added to the cells and the tubes were used for this study. UCI-101 and UCI-107 have been were incubated for 30 min. Following two washings in assay previously characterized [13, 14] and were kindly provided buffer, the final cell pellet was resuspended in 500 ml assay by Dr. Alberto Manetta, University of California, Irvine.
buffer for subsequent analysis. Cells were analyzed with a SKOV-3 was purchased from American Type Culture Colfluorescence-activated cell sorter (FACS; Becton-Dickinlection (ATCC), while T-222 was kindly provided by Dr.
son) [15] with a 15-mW argon laser with an excitation of Benjamin Bonavida, University of California, Los Angeles. All tumor cell lines were maintained at 37ЊC, 5% CO 2 in 488 nm. Fluorescent signals were gated on the basis of for-ward and right-angle light scattering to eliminate dead cells and aggregates from analysis. Gated signals (10 4 ) were detected at 585-bp filter and analyzed using Lysis II software.
Statistical analysis. Significance analysis was performed using a paired Student's t test. Expression of surface antigens after high-dose gamma irradiation. Cell surface antigen expression on the four established cell lines was evaluated 2 days after irradiation and the results were compared to the level of expression on unirradiated control cells. As shown in Figs. 1-3 , irradiation with 10,000 cGy caused a significant upregulation of all the surface antigens expressed prior to irradiation. The induction indices for MHC Class I ranged from 1.42 to 2.62, for ICAM-1 from 1.74 to 2.20, and for Her2-neu from 1.22 to 1.71, respectively. It is interesting that irradiation did not induce neoexpression of antigens previously not present on these cells, such as MHC Class II. In one cell line (i.e., T-222), irradiation-induced upregulation was also noted at 5000 cGy and was essentially identical to that found at 10,000 cGy. However, because 5000 cGy was not a sufficient dose to totally block cell replication in some cell lines, we performed the majority of our studies using 10,000 cGy, a dose which consistently blocked cell replication in all cell lines.
RESULTS

Expression
Kinetics of expression of surface antigens after high-dose gamma irradiation. Kinetics studies were performed to de- Thus, tumor cells from the T-222 cell line were irradiated with 10,000 cGy and analyzed for antigen expression 2 and studies showed that the enhancement of antigen expression 6 days after irradiation. As seen in Fig. 4 , irradiation of these was persistent until all cells died (data not shown). cells caused increased expression of all the surface antigens at Day 2 as well as Day 6 when compared to the levels expressed by the unirradiated parental cells. Viability studies DISCUSSION (trypan blue exclusion) showed that by Day 2 the viability of the irradiated cells was approximately 90% and this
The importance of surface antigen expression and immune recognition has been underscored by studies on human tumor dropped to about 30% by Day 6 after 10,000 cGy. Additional Irradiation, together with surgery and chemotherapy, represents one of the most commonly used, standardized, and effective modalities for contemporary cancer therapy. However, in a significant number of cases where whole-body irradiation with fractionated low doses is used (i.e., malignant lymphoma) the efficacy of the therapy cannot be explained merely by the lethal effects of radiation on the tumor cells [17] . There may be additional reasons to explain these findings. Reports dating more than two decades ago note an increased infiltration of lymphocytes surrounding tumor cells following radiation therapy, suggesting that such cells may have become more immunogenic [18, 19] . Most reports evaluating the phenotype of such tumor-infiltrating cells have shown that the majority of these cells are CD 4
/ helper inducer T cells [20] . Cameron et al. [21] reported that local tumor irradiation synergizes with tumor-infiltrating lymphocytes (TIL) and IL-2 administration in mediating the regression of established macrometastases. Such results support the possibility that the synergy observed between local irradiation and the systemic administration of IL-2 and TIL cells may be due in part to the upregulated expression of cell surface antigens on the irradiated tumor cells. Indeed, such cells exposed to TNF-a plus IFN-g [4, 5, 16] . Such studies have shown that the induction of cytotoxic effector cells requires a higher level of antigen expression than cytotoxic interaction. In fact, tumors not previously considered to be immunogenic but so induced to express higher levels of MHC antigens appear to recruit high-avidity T cells, which can then recognize target cells which express virtually undetectable levels of these surface antigens [4, 5] . Moreover, in studies on melanoma [5, 6] the expression of ICAM-1 antigens in different melanoma clones correlated with the susceptibility of the tumor cells to lysis by specific and nonspecific T-cell clones and, more importantly, upregulation of these antigens, by treatment with interferon-g in low expressor clones, could boost tumor lysability only by specific, TCR-dependent and HLA-restricted effector cells. In such studies, the relative surface expression of ICAM-1 was a key factor for the outcome of the interaction with T cells and only those clones that expressed these molecules at lev- a phenomenon would render these cells more recognizable animals against a subsequent challenge of viable parental cells, even though the unirradiated tumor cells were considby the IL-2-activated, MHC Class I-restricted cytotoxic T lymphocytes. However, adequate documentation of the ef-ered to be poorly immunogenic. Such data support the concept that following irradiation important cell surface changes fects of irradiation on surface antigen expression is lacking.
Further studies documenting the effects of irradiation on occur which alter the intrinsic immunogenicity of the tumor cells. In addition to these findings, the necessity of blocking tumor immunogenicity were recently reported by Dranoff et al. and Huang et al. [7, 8] who showed that immunogenicity cell replication in any human clinical immunotherapy trial using whole-cell tumor vaccines has directed our interest of irradiated tumor cells was increased and would protect will ultimately determine the validity of this approach.
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